138 related articles for article (PubMed ID: 15788295)
1. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
Pentheroudakis G; Briasoulis E; Karavassilis V; Fountzilas G; Xeros N; Samelis G; Samantas E; Pavlidis N
Acta Oncol; 2005; 44(2):155-60. PubMed ID: 15788295
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
[TBL] [Abstract][Full Text] [Related]
3. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
4. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
5. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Pavlidis N
Ann Oncol; 2012 Sep; 23 Suppl 10():x282-5. PubMed ID: 22987978
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
Cashin PH; Graf W; Nygren P; Mahteme H
Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
[TBL] [Abstract][Full Text] [Related]
7. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
[TBL] [Abstract][Full Text] [Related]
8. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
[TBL] [Abstract][Full Text] [Related]
9. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with cancer of unknown primary site.
Hainsworth JD; Greco FA
Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
[TBL] [Abstract][Full Text] [Related]
14. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
15. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study.
Lemmens VE; Klaver YL; Verwaal VJ; Rutten HJ; Coebergh JW; de Hingh IH
Int J Cancer; 2011 Jun; 128(11):2717-25. PubMed ID: 20715167
[TBL] [Abstract][Full Text] [Related]
16. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
Glehen O; Kwiatkowski F; Sugarbaker PH; Elias D; Levine EA; De Simone M; Barone R; Yonemura Y; Cavaliere F; Quenet F; Gutman M; Tentes AA; Lorimier G; Bernard JL; Bereder JM; Porcheron J; Gomez-Portilla A; Shen P; Deraco M; Rat P
J Clin Oncol; 2004 Aug; 22(16):3284-92. PubMed ID: 15310771
[TBL] [Abstract][Full Text] [Related]
18. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
da Silva RG; Sugarbaker PH
J Am Coll Surg; 2006 Dec; 203(6):878-86. PubMed ID: 17116556
[TBL] [Abstract][Full Text] [Related]
19. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
